Weill Cornell Lymphoma Program

Home
Weill Cornell Lymphoma Program

Enabling patients with lymphoma to have the best possible clinical outcomes.

The Lymphoma Program at Weill Cornell Medical College/NewYork-Presbyterian Hospital, located on the Upper East Side of New York City, is internationally recognized for our efforts to enable patients with non-Hodgkin’s lymphoma, Hodgkin’s disease and related disorders to have the best possible clinical outcome, including cure when possible. The goal of our page and blog is to provide you with up-to-date information about the latest developments in lymphoma treatment and research.

08/08/2025

ICYMI: the combination of nivolumab + AVD outperformed a brentuximab vedotin based regimen in older patients with classic according to led by Dr. Sarah Rutherford: https://bit.ly/3UHaGW0 (cc: Targeted Oncology)

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

06/08/2025

led by Dr. Sarah Rutherford compared two different combination treatment regimens for advanced classical patients over the age of 60:

In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD vs brentuximab vedotin plus...

27/06/2025

Results from a showed that second-line sintilimab plus beat chemotherapy alone in subset of patients. Dr. Sarah Rutherford commented on these results:

Use of the PD-1 inhibitor sintilimab in combination with ICE chemotherapy as a second-line treatment in classical Hodgkin lymphoma shows impressive response rates vs chemo alone in the phase 3 ORIENT-21 trial.

$Dr. Sarah Rutherford weighed in on presented at evaluating a new combination therapy regiment for relapsed or refrac...$

25/06/2025

Dr. Sarah Rutherford weighed in on presented at evaluating a new combination therapy regiment for relapsed or refractory patients with poor prognoses:

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response rates in patients with few other remaining treatment choices.

11/02/2025

Watch Dr. Jia Ruan talk about long-term follow-up combining azacitidine with CHOP for previously untreated peripheral T-cell : https://bit.ly/3WK19yP (cc: VJHemOnc)

Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, comments on the long-term follow-up of a Phase...

07/02/2025

Dr. Jia Ruan spoke with VJHemOnc about a phase 2 evaluating a novel triplet combination for mantle cell ( ):

Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, comments on a Phase II trial (NCT03863184) of...

03/02/2025

LISTEN: Dr. Jia Ruan participated in the VJHemOnc to discuss non-Hodgkin updates from the 2024 American Society of Hematology Annual Meeting

Today’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and...

04/10/2024

Join our experts at Lymphoma Research Foundation upcoming in-person patient education forum. Connect with others with your same diagnosis and hear from global leaders about the latest treatment and advances. Learn more & register: lymphoma.org/edforum

$Dr. John Leonard discussed the latest targeted therapies for relapsed/refractory at the 2024 Great Debates & Updates ...$

20/06/2024

Dr. John Leonard discussed the latest targeted therapies for relapsed/refractory at the 2024 Great Debates & Updates . Read the key takeaways:

An abstract is unavailable.

10/01/2024

Dr. Richard Furman recently presented data at the Chemotherapy Foundation Symposium on frontline Bruton’s Tyrosine Kinase (BTK) inhibitor selection for chronic lymphocytic ( ):

Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic ...

08/01/2024

ICYMI: Weill Cornell Medicine/NewYork-Presbyterian Hospital experts Drs. Sarah Rutherford and Leandro Cerchietti published examining how a new treatment strategy may improve outcomes for treatment-resistant diffuse large B-cell .

Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of mess...

05/01/2024

Dr. John Allan spoke to OncLive about fixed-duration treatment approaches with Bruton’s Tyrosine Kinase (BTK) inhibitors and BCL2 inhibitors for patients with chronic lymphocytic ( ):

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Address

520 East 70th Street, Starr Pavilion, 3rd Floor

10065

Website

https://cornell-lymphoma.com/

Alerts

Be the first to know and let us send you an email when Weill Cornell Lymphoma Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Address
Alerts
Contact The Practice
Claim ownership or report listing
Want your practice to be the top-listed Clinic?

Country:

City:

Our Story

The Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is one of the leading clinical and scientific research centers in the world. The renowned experts that comprise our team are committed to delivering compassionate, cutting-edge care to improve the lives of people with lymphoma before, during and for years after treatment.

We are not content to care only for current lymphoma patients; we also actively pursue medical advances that will alleviate the suffering of those affected by the disease in the future. Whether acting as your primary oncologist, working in tandem with your oncologist or primary physician, overseeing your participation in a clinical trial or providing a second opinion, we are pleased to help all patients achieve the best possible results.